171 related articles for article (PubMed ID: 30038895)
1. Gram scale preparation of clozapine
van der Peet PL; Gunawan C; Abdul-Ridha A; Ma S; Scott DJ; Gundlach AL; Bathgate RAD; White JM; Williams SJ
MethodsX; 2018; 5():257-267. PubMed ID: 30038895
[TBL] [Abstract][Full Text] [Related]
2. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
3. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
Elife; 2023 Mar; 12():. PubMed ID: 36892930
[TBL] [Abstract][Full Text] [Related]
4. DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs
Thompson KJ; Khajehali E; Bradley SJ; Navarrete JS; Huang XP; Slocum S; Jin J; Liu J; Xiong Y; Olsen RHJ; Diberto JF; Boyt KM; Pina MM; Pati D; Molloy C; Bundgaard C; Sexton PM; Kash TL; Krashes MJ; Christopoulos A; Roth BL; Tobin AB
ACS Pharmacol Transl Sci; 2018 Sep; 1(1):61-72. PubMed ID: 30868140
[TBL] [Abstract][Full Text] [Related]
5. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.
Raper J; Morrison RD; Daniels JS; Howell L; Bachevalier J; Wichmann T; Galvan A
ACS Chem Neurosci; 2017 Jul; 8(7):1570-1576. PubMed ID: 28324647
[TBL] [Abstract][Full Text] [Related]
7. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
eNeuro; 2016; 3(5):. PubMed ID: 27822508
[TBL] [Abstract][Full Text] [Related]
8. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
[TBL] [Abstract][Full Text] [Related]
9. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
[TBL] [Abstract][Full Text] [Related]
10. DREADD-based synthetic control of chondrocyte calcium signaling in vitro.
McDonough RC; Shoga JS; Price C
J Orthop Res; 2019 Jul; 37(7):1518-1529. PubMed ID: 30908734
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent reduction in cocaine-induced locomotion by Clozapine-N-Oxide in rats with a history of cocaine self-administration.
Padovan-Hernandez Y; Knackstedt LA
Neurosci Lett; 2018 May; 674():132-135. PubMed ID: 29571824
[TBL] [Abstract][Full Text] [Related]
12. G
Marciante AB; Farmer GE; Cunningham JT
J Neurophysiol; 2020 Aug; 124(2):591-609. PubMed ID: 32697679
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.
Jendryka M; Palchaudhuri M; Ursu D; van der Veen B; Liss B; Kätzel D; Nissen W; Pekcec A
Sci Rep; 2019 Mar; 9(1):4522. PubMed ID: 30872749
[TBL] [Abstract][Full Text] [Related]
14. Chemogenetic Activation of Excitatory Neurons Alters Hippocampal Neurotransmission in a Dose-Dependent Manner.
Pati S; Salvi SS; Kallianpur M; Vaidya B; Banerjee A; Maiti S; Clement JP; Vaidya VA
eNeuro; 2019; 6(6):. PubMed ID: 31645362
[TBL] [Abstract][Full Text] [Related]
15. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.
Manvich DF; Webster KA; Foster SL; Farrell MS; Ritchie JC; Porter JH; Weinshenker D
Sci Rep; 2018 Mar; 8(1):3840. PubMed ID: 29497149
[TBL] [Abstract][Full Text] [Related]
16. Repeated chemogenetic activation of dopaminergic neurons induces reversible changes in baseline and amphetamine-induced behaviors.
Chohan MO; Fein H; Mirro S; O'Reilly KC; Veenstra-VanderWeele J
Psychopharmacology (Berl); 2023 Dec; 240(12):2545-2560. PubMed ID: 37594501
[TBL] [Abstract][Full Text] [Related]
17. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor.
Nakajima K; Wess J
Mol Pharmacol; 2012 Oct; 82(4):575-82. PubMed ID: 22821234
[TBL] [Abstract][Full Text] [Related]
18. Chronic hM3Dq signaling in microglia ameliorates neuroinflammation in male mice.
Binning W; Hogan-Cann AE; Yae Sakae D; Maksoud M; Ostapchenko V; Al-Onaizi M; Matovic S; Lu WY; Prado MAM; Inoue W; Prado VF
Brain Behav Immun; 2020 Aug; 88():791-801. PubMed ID: 32434046
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of a chemogenetically modified G protein-coupled receptor.
Abdul-Ridha A; Lane JR; Sexton PM; Canals M; Christopoulos A
Mol Pharmacol; 2013 Feb; 83(2):521-30. PubMed ID: 23197649
[TBL] [Abstract][Full Text] [Related]
20. Oral application of clozapine-N-oxide using the micropipette-guided drug administration (MDA) method in mouse DREADD systems.
Schalbetter SM; Mueller FS; Scarborough J; Richetto J; Weber-Stadlbauer U; Meyer U; Notter T
Lab Anim (NY); 2021 Mar; 50(3):69-75. PubMed ID: 33619409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
